Analyst Coverage
- Overview
- Stock Information
- News & Events
- SEC Filings
- Analyst Coverage
- Corporate Governance
- Shareholder Services
- Corporate Presentation
Viking Therapeutics, Inc. is covered by the following analysts:
| BTIG | Justin Zelin | 212-738-6189 |
| H.C. Wainwright & Co. | Joseph Pantginis, Ph.D. | 646-975-6968 |
| Jefferies | Roger Song, M.D., CFA | 617-342-7955 |
| J.P. Morgan | Hardik Parikh, CFA | 212-622-2875 |
| Laidlaw & Company | Yale Jen, Ph.D. | 212-953-4978 |
| Leerink Partners | Thomas J. Smith | 212-277-6069 |
| Maxim Group | Jason McCarthy, Ph.D. | 212-895-3556 |
| Morgan Stanley | Michael E. Ulz | 212-761-4650 |
| Oppenheimer | Jay Olson, CFA | 212-667-8126 |
| Raymond James | Steven Seedhouse, Ph.D. | 212-885-1837 |
| Stifel | Annabel Samimy | 212-271-3823 |
| Truist Securities | Joon Lee, M.D., Ph.D. | 212-303-0139 |
| William Blair | Andy Hsieh, Ph.D. | 312-364-5051 |
Please note, that any opinions, estimates or forecasts regarding performance made by these analysts do not represent Viking Therapeutics or its management team. Viking Therapeutics is under no obligation to update this list, thus it may not be complete or up to date.